CL2011003191A1 - Uso de (6r)-2-amino-4,5,6,7- tetrahidro-6- (propilamino)benzotiazol (dexpramipexol) o sus sales para preparar un medicamento util para tratar la esclerosis lateral amiotrofica. - Google Patents

Uso de (6r)-2-amino-4,5,6,7- tetrahidro-6- (propilamino)benzotiazol (dexpramipexol) o sus sales para preparar un medicamento util para tratar la esclerosis lateral amiotrofica.

Info

Publication number
CL2011003191A1
CL2011003191A1 CL2011003191A CL2011003191A CL2011003191A1 CL 2011003191 A1 CL2011003191 A1 CL 2011003191A1 CL 2011003191 A CL2011003191 A CL 2011003191A CL 2011003191 A CL2011003191 A CL 2011003191A CL 2011003191 A1 CL2011003191 A1 CL 2011003191A1
Authority
CL
Chile
Prior art keywords
propylamino
benzothiazole
tetrahydro
salts
amino
Prior art date
Application number
CL2011003191A
Other languages
English (en)
Spanish (es)
Inventor
Valentin Bozik Michael E Gribkoff
Original Assignee
Knopp Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43356795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003191(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knopp Neurosciences Inc filed Critical Knopp Neurosciences Inc
Publication of CL2011003191A1 publication Critical patent/CL2011003191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011003191A 2009-06-19 2011-12-16 Uso de (6r)-2-amino-4,5,6,7- tetrahidro-6- (propilamino)benzotiazol (dexpramipexol) o sus sales para preparar un medicamento util para tratar la esclerosis lateral amiotrofica. CL2011003191A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21865909P 2009-06-19 2009-06-19
US26794509P 2009-12-09 2009-12-09
US31711810P 2010-03-24 2010-03-24
US35643910P 2010-06-18 2010-06-18

Publications (1)

Publication Number Publication Date
CL2011003191A1 true CL2011003191A1 (es) 2012-07-20

Family

ID=43356795

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003191A CL2011003191A1 (es) 2009-06-19 2011-12-16 Uso de (6r)-2-amino-4,5,6,7- tetrahidro-6- (propilamino)benzotiazol (dexpramipexol) o sus sales para preparar un medicamento util para tratar la esclerosis lateral amiotrofica.

Country Status (12)

Country Link
US (2) US20110009460A1 (enExample)
EP (1) EP2442655A4 (enExample)
JP (1) JP2012530723A (enExample)
CN (1) CN102802418A (enExample)
AU (1) AU2010262970A1 (enExample)
BR (1) BRPI1010084A2 (enExample)
CA (1) CA2765876A1 (enExample)
CL (1) CL2011003191A1 (enExample)
CO (1) CO6480953A2 (enExample)
MX (1) MX2011013577A (enExample)
RU (1) RU2012101792A (enExample)
WO (1) WO2010148409A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
EA028060B1 (ru) * 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013096870A1 (en) * 2011-12-22 2013-06-27 Knopp Neurosciences Inc Compositions and methods for treating amyotrophic lateral sclerosis
WO2014134569A1 (en) * 2013-02-28 2014-09-04 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CA2918035C (en) 2013-07-12 2023-01-03 Knopp Biosciences Llc Use of dexpramipexole in the treatment of disorders associated with elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3033081T3 (da) * 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
EP3071199A2 (en) * 2013-11-22 2016-09-28 Genzyme Corporation Novel methods for treating neurodegenerative diseases
WO2016040643A1 (en) * 2014-09-10 2016-03-17 The Uab Research Foundation Amyotrophic lateral sclerosis (als) biomarkers and uses thereof
WO2016207924A1 (en) * 2015-06-25 2016-12-29 Chiarugi Alberto Dexpramipexole for the treatment of pain
WO2017103224A1 (en) * 2015-12-16 2017-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of treatment of amyotrophic lateral sclerosis
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0186087B1 (de) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4904475A (en) * 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
EP0249343B1 (en) * 1986-06-13 1992-01-08 Alza Corporation Moisture activation of transdermal drug delivery system
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4917895A (en) * 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
EP0387751B1 (en) * 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FI945311L (fi) * 1992-05-13 1994-11-11 Alza Corp Oksibutyniinin transdermaalinen annostelu
US5442117A (en) * 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US5804215A (en) * 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CA2375843A1 (en) * 1999-06-04 2000-12-14 Qi Zhao Compositions and methods for inhibiting cell death
US6480820B1 (en) * 1999-09-20 2002-11-12 Advanced Cochlear Systems, Inc. Method of processing auditory data
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
AU2001233156A1 (en) * 2000-02-01 2001-08-14 Human Genome Sciences, Inc. Bcl-2-like polynucleotides, polypeptides, and antibodies
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6598123B1 (en) * 2000-06-28 2003-07-22 Intel Corporation Snoop filter line replacement for reduction of back invalidates in multi-node architectures
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
DE60231386D1 (de) * 2001-04-09 2009-04-16 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
HUP0500001A3 (en) * 2001-12-11 2005-11-28 Univ Virginia Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
CN100571695C (zh) * 2002-01-16 2009-12-23 贝林格尔英格海姆法玛两合公司 含有替米沙坦和利尿剂的双层药片及其制备方法
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
GB0221513D0 (en) * 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US7365086B2 (en) * 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20050053649A1 (en) * 2003-09-08 2005-03-10 Anne-Marie Chalmers Medication delivery device
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US20080096939A1 (en) * 2004-07-03 2008-04-24 Andreas Keil Process For Preparation Of Pramipexole By Chiral Chromatography
EA201001086A1 (ru) * 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
DE102004044578A1 (de) * 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
US20060069263A1 (en) * 2004-09-30 2006-03-30 Irina Gribun Process for the reduction of (S)-2-amino-6-propionamido-4,5,6,7-tetrahydrobenzo-thiazole
EA013053B1 (ru) * 2004-11-05 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Двуслойная таблетка, содержащая телмисартан и амлодипин
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
ES2310146B1 (es) * 2004-12-30 2009-11-11 Chemagis Ltd. Nuevo procedimiento para preparar pramipexol y su mezcla isomerica optica mediante reduccion con triacetoxiborohidruro de sodio.
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
WO2007046347A1 (ja) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. 筋萎縮性側索硬化症患者の運動神経保護用医薬
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) * 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008042611A2 (en) * 2006-09-29 2008-04-10 Centocor, Inc. Method of using il6 antagonists with mitoxantrone for prostate cancer
RU2491068C2 (ru) * 2006-12-14 2013-08-27 Нопп Ньюросайенсиз, Инк. Композиции и способы применения (r)-прамипексола
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) * 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
AU2008224869A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same

Also Published As

Publication number Publication date
CN102802418A (zh) 2012-11-28
RU2012101792A (ru) 2013-07-27
WO2010148409A1 (en) 2010-12-23
JP2012530723A (ja) 2012-12-06
EP2442655A1 (en) 2012-04-25
US20130245081A1 (en) 2013-09-19
AU2010262970A1 (en) 2012-01-12
MX2011013577A (es) 2012-04-10
US20110009460A1 (en) 2011-01-13
BRPI1010084A2 (pt) 2015-08-25
EP2442655A4 (en) 2013-04-03
CO6480953A2 (es) 2012-07-16
CA2765876A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
CL2011003191A1 (es) Uso de (6r)-2-amino-4,5,6,7- tetrahidro-6- (propilamino)benzotiazol (dexpramipexol) o sus sales para preparar un medicamento util para tratar la esclerosis lateral amiotrofica.
CL2019001842A1 (es) Nuevos derivados de fenilo.
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CR20140537A (es) Compuesto heterocíclico nitrogenado
UY32045A (es) Compuesto amida
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
CL2010001368A1 (es) Compuestos derivados de 1,3-tiazina; composicion farmaceutica que lo comprende; utiles para inhibir a la beta-secretasa
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
CL2016002970A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo.
JOP20210050A1 (ar) معدلات تعبير pnpla3
CO6650337A2 (es) Derivados de 3- hidroxi-5 -arilisotiazol novedoso
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CO6640320A2 (es) Composición de control de fitoenfermedades y metodo de control de fitoenfermedades
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
CL2012000026A1 (es) Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus.
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
CO6400224A2 (es) Purificación de 1-[2-(2-4-dimetilfenilsulfanil)fenil]piperazina
CO6362011A2 (es) Compuesto de anillo fusionado y su uso
SI3240538T1 (sl) Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CO2019012125A2 (es) Inhibidores ip6k
CO2022009787A2 (es) Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
CR10137A (es) Agente terapéutico para la diabetes